ABCL - Latest News
AbCellera Biologics Inc. (ABCL), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.46B. Beta to the broader market is 1.03.
The article list below shows the most recent ABCL headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ABCL Headlines
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
zacks.com - May 14, 2026
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd.
AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com - May 14, 2026
AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 12, 2026
AbCellera Biologics Inc.
AbCellera Biologics Q1 Earnings Call Highlights
marketbeat.com - May 11, 2026
AbCellera Biologics NASDAQ: ABCL said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data f
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
zacks.com - May 11, 2026
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.
How News Affects ABCL Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ABCL's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ABCL news questions
- What is the latest ABCL news headline?
- The most recent ABCL headline (May 14, 2026) is "Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ABCL news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ABCL news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ABCL options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.